Soon after the outbreak of COVID-19, Hoffmann et al. demonstrated that SARS-CoV-2′s dependence on TMPRSS2 for cell entry can be blocked by a clinically proven protease inhibitor, Camostat [3]. This evidence concerns the gene TMPRSS2 and COVID-19.